MWG Caph Ltd — 13F Holdings & Portfolio

CIK 2111120 · latest 13F-HR filed 2026-02-17

MWG Caph Ltd manages $72.4M in 13F-reported U.S. long-equity assets across 3 reported positions as of its 2025-12-31 13F-HR filing. Its largest disclosed positions are BEAM (48.53%), LYEL (42.88%), PRME (8.59%).

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$72.4M

Long-equity book

Holdings
3

Distinct positions

Period
2025-12-31

Filed 2026-02-17

Q/Q Activity
—

no prior filing cached

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • —
Show all →

Top Trims

  • —
Show all →

New Positions

  • —
Show all →

Exited Positions

  • —
Show all →

MWG Caph Ltd Holdings (2025-12-31)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 BEAM THERAPEUTICS INC BEAM 07373V105 $35.1M 48.53% 1,266,934 SH
2 LYELL IMMUNOPHARMA INC LYEL 55083R203 $31.0M 42.88% 1,008,116 SH
3 PRIME MEDICINE INC PRME 74168J101 $6.2M 8.59% 1,792,210 SH